Home » Health & Medicine, Manufacturing & Industry, Marketing & Sales, Pharmaceuticals & Biotech, World » Pol Polyprotein Market Report 2016: Industry Size, Share, Definition, Pipeline Review, H1 2016 by Radiant Insights
“Radiant Insights”
RadiantInsights.com includes new market research report on “Pol Polyprotein Market Report 2016” to its huge collection of research reports.

Summary
Global Markets Direct’s, ‘Pol Polyprotein – Pipeline Review, H1 2016’, provides in depth analysis on Pol Polyprotein targeted pipeline therapeutics.

The report provides comprehensive information on the Pol Polyprotein, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Pol Polyprotein targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Click For Report Details @ http://www.radiantinsights.com/research/pol-polyprotein-pipeline-review-h1-2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
– The report provides a snapshot of the global therapeutic landscape for Pol Polyprotein
– The report reviews Pol Polyprotein targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Pol Polyprotein targeted therapeutics and enlists all their major and minor projects
– The report assesses Pol Polyprotein targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Pol Polyprotein targeted therapeutics

Reasons To Buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Pol Polyprotein
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Pol Polyprotein development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Related Reports by Radiant Insights:
5′-Nucleotidase (CD73 or Ecto-5′-Nucleotidase or EC 3.1.3.5) – Pipeline Review, H1 2016 –
http://www.radiantinsights.com/research/5-nucleotidase-cd73-or-ecto-5-nucleotidase-or-ec-3-1-3-5-pipeline-review-h1-2016

Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) – Pipeline Review, H1 2016 –
http://www.radiantinsights.com/research/glutamate-carboxypeptidase-2

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pol Polyprotein Overview 6
Therapeutics Development 7
Pol Polyprotein – Products under Development by Stage of Development 7
Pol Polyprotein – Products under Development by Therapy Area 8
Pol Polyprotein – Products under Development by Indication 9
Pol Polyprotein – Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Pol Polyprotein – Products under Development by Companies 12
Pol Polyprotein – Products under Development by Universities/Institutes 14
Pol Polyprotein – Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Pol Polyprotein – Companies Involved in Therapeutics Development 21
GeoVax Labs, Inc. 21
Inovio Pharmaceuticals, Inc. 22
Johnson & Johnson 23
Pol Polyprotein – Drug Profiles 24
GOVXB-11 – Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
GOVXC-11 – Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
GOVXC-21 – Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
HIV [serotype Ad26] (tetravalent) vaccine – Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
HIV-1 (bivalent) vaccine – Drug Profile 30
Product Description 30

Buy a Sample copy of This Report @ http://www.radiantinsights.com/research/pol-polyprotein-pipeline-review-h1-2016/request-sample

About Us:
Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Media Contact
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Email: sales@radiantinsights.com
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: California
Country: United States
Website: http://www.radiantinsights.com/research/pol-polyprotein-pipeline-review-h1-2016

Comments are closed.